Early safety assessment using cellular systems biology yields insights into mechanisms of action

Journal of Biomolecular Screening

Volumn 15, Issue 7, 2010, Pages 783-797

  Giuliano, Kenneth A ^a   Gough, Albert H ^a   Lansing Taylor, D ^a   Vernetti, Lawrence A ^a   Johnston, Patricia A ^a  

^a Cellumen Inc   (United States)

Author keywords

biomarker relationships; cellular systems biology; high content screening; safety risk index; toxic response

Indexed keywords

ANTIMYCIN A1; BIOLOGICAL MARKER; GEMFIBROZIL; IRINOTECAN; NEFAZODONE; PIMOZIDE;

ARTICLE; CELL HETEROGENEITY; CELL POPULATION; CELL STRAIN HEPG2; CYTOLOGY; CYTOTOXICITY; HIGH CONTENT SCREENING; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; RODENT; SCREENING; SYSTEMS BIOLOGY; TOXICOLOGY;

ANIMALS; BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; CELL MEMBRANE PERMEABILITY; DRUG TOXICITY; HEP G2 CELLS; HEPATOCYTES; HUMANS; LYSOSOMES; MEMBRANE POTENTIAL, MITOCHONDRIAL; RATS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; SYSTEMS BIOLOGY; TIME FACTORS;

RODENTIA;

EID: 77956046289     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057110376413     Document Type: Article

References (24)

1. Giuliano KA, DeBiasio RL, Dunlay RT, Gough A., Volosky JM, Zock J., et al. High-content screening: a new approach to easing key bottlenecks in the drug discovery process. J Biomol Screen 1997 ; 2: 249-259.
2. Plymale DR, Haskins JR, de la Iglesia FA: Monitoring simultaneous subcellular events in vitro by means of coherent multiprobe fluorescence. Nat Med 1999 ; 5: 351-355.
3. OBrien PJ, Irwin W., Diaz D., Howard-Cofield E., Krejsa CM, Slaughter MR., et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol 2006 ; 80: 580-604.
4. Xu JJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, de Graaf D.: Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 2008 ; 105: 97-105.
5. Vernetti L., Irwin W., Giuliano K., Gough A., Johnston K., Taylor D.: Cellular systems biology applied to preclinical safety testing: a case study of CellCiphr profiling. In Ekins S, Xu J (eds): Drug Efficacy, Safety, and Biologics Discovery. Hoboken, NJ: John Wiley, 2009: 53-74.
6. Giuliano KA, Cheung WS, Curran DP, Day BW, Kassick AJ, Lazo JS., et al. Systems cell biology knowledge created from high content screening. Assay Drug Dev Technol 2005 ; 3: 501-514.
7. Rubin H.: What keeps cells in tissues behaving normally in the face of myriad mutations? Bioessays 2006 ; 28: 515-524.
8. Giuliano KA, Chen YT, Taylor DL: High-content screening with siRNA optimizes a cell biological approach to drug discovery: defining the role of p53 activation in the cellular response to anticancer drugs. J Biomol Screen 2004 ; 9: 557-568.
9. Perlman ZE, Slack MD, Feng Y., Mitchison TJ, Wu LF, Altschuler SJ: Multidimensional drug profiling by automated microscopy. Science 2004 ; 306: 1194-1198.
10. Altschuler SJ, Wu LF: Cellular heterogeneity: do differences make a difference ? Cell 2010 ; 141: 559-563.
11. Gomez-Lechon MJ, Castell JV, Donato MT: Hepatocytes-the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo. Chem Biol Interact 2007 ; 168: 30-50.
12. Berry M., Edwards A., Barritt G.: High-yield preparation of isolated hepatocytes from rat liver. In Burdon R, van Knippenbert P (eds): Isolated Hepatocytes Preparation, Properties and Applications. Amsterdam: Elsevier, 1991: 15-58.
13. Tedeschi H.: Mitochondrial membrane potential: evidence from studies with a fluorescent probe. Proc Natl Acad Sci U S A 1974 ; 71: 583-585.
14. Knapp T., Zlokarnik G., Negulescu P., Tsien R., Rink T.: Photon reducing agents for fluorescence assays. US patent 7067324, 2006.
15. Blom WM, de Bont HJ, Nagelkerke JF: Regional loss of the mitochondrial membrane potential in the hepatocyte is rapidly followed by externalization of phosphatidylserines at that specific site during apoptosis. J Biol Chem 2003 ; 278: 12467-12474.
16. Rottenberg H., Covian R., Trumpower BL: Membrane potential greatly enhances superoxide generation by the cytochrome bc1 complex reconstituted into phospholipid vesicles. J Biol Chem 2009 ; 284: 19203-19210.
17. Dykens JA, Jamieson JD, Marroquin LD, Nadanaciva S., Xu JJ, Dunn MC., et al. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol Sci 2008 ; 103: 335-345.
18. Kostrubsky SE, Strom SC, Kalgutkar AS, Kulkarni S., Atherton J., Mireles R., et al. Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol Sci 2006 ; 90: 451-459.
19. Greene DS, Barbhaiya RH: Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet 1997 ; 33: 260-275.
20. Berson A., Renault S., Letteron P., Robin MA, Fromenty B., Fau D., et al. Uncoupling of rat and human mitochondria: a possible explanation for tacrine-induced liver dysfunction. Gastroenterology 1996 ; 110: 1878-1890.
21. Galisteo M., Rissel M., Sergent O., Chevanne M., Cillard J., Guillouzo A., et al. Hepatotoxicity of tacrine: occurrence of membrane fluidity alterations without involvement of lipid peroxidation. J Pharmacol Exp Ther 2000 ; 294: 160-167.
22. Robertson DG, Braden TK, Urda ER, Lalwani ND, de la Iglesia FA: Elucidation of mitochondrial effects by tetrahydroaminoacridine (tacrine) in rat, dog, monkey and human hepatic parenchymal cells. Arch Toxicol 1998 ; 72: 362-371.
23. Li Z., Agellon LB, Allen TM, Umeda M., Jewell L., Mason A., et al. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab 2006 ; 3: 321-331.
24. Nobuyuki M., Tetsuhito M., Yoshiharu Y., Naoto O., Yasuhisa F., Yasuhiro T., et al. Effects of chlorpromazine on plasma membrane permeability and fluidity in the rat brain: a dynamic positron autoradiography and fluorescence polarization study. Prog Neur Psychopharmacol Biol Psych 2007 ; 31: 178-186.